PTO/SB/08a (08-03)

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

AUG 0 3 2006 -

1

Translation is attached

Sheet

Complete if Known Application Number 10/596,479 Filing Date June 14, 2006 First Named Inventor Bradley L. Urguhart et al. Art Unit N/A Examiner Name Attomey Docket Number 10935-35

(Use as many sheets as necessary)

of 2

U.S. PATENT DOCUMENTS Name of Patentee or Applicant of Cited Document Document Number Exemine Initiels * Peges, Columns, Lines, Where Relevant MM-DD-YYYY Passages or Relevent Figures Appear Number - Kind Code² (if known) US-US-USus-US-US-US-US-USus-

		FOREIGN PA	TENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Dete MM-DD-YYYY	Applicant of Cited Document		
/TPT/		WO 01/30352	05-03-2001	Cary Pharmaceuticals Inc.		
/TPT/		CA 2,265,926	10-08-2000	Khan		
			-			

Examiner Signature	/Timothy Thomas/	Date Considered	5/5/2008				
EXAMPER: Initial if reference considered, whether or not classins is no conformance with MEPE 600. Draw line through citation if not in conformance and not considered included copy of this form with next communication to applicant. "Applications unjust collained designation unjust collained designation unjust collained designation unjust collained collained and unjust the conformance and unjust t							

Translation is attached.

This collection of information is required by 7 CFR 157 and 158. The information is required to obtain or retain is soorfit by the public whom is to rise and by the This collection of information in required by 3 LIS. AT 25 and 3 CFR 1.14 This collection is explored by the public whole his by the public whole is a size of the public whole

PTO/SB/08b/08-03)

Approved for use through 07/31/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known		
INFORMATION DIGGI COURT	Application Number	10/596,479		
INFORMATION DISCLOSURE	Filing Date	June 14, 2006		
STATEMENT BY APPLICANT	First Named Inventor	Bradley L. Urguhart et al.		
	Art Unit	N/A		
(Use as many sheets as necessary)	Examiner Name			
Sheet 2 of 2	Attorney Docket Number	10935-35		

. آم

Examiner

/Timothy Thomas/

		NON PATENT LITERATURE DOCUMENTS			
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	e T²		
/TPT/	1.	Abstracts: First Canadian Therapeutics Congress, Can. J. Clin. Pharmacol., 2004, pp. e47-e48, e67-e88, Vol. 11, No. 1.			
	2.	HOUSE, James D. et al., "Renal uptake and excretion of homocysteine in rats with acute hyperhomocysteinemia", Kidney International", 1998, pp.1601-1607, Vol. 54.			
	3.	SMITH, Patrick F. et al., "Pharmacokinetics and Pharmacodynamics of Mesna-Mediated Plasma Cysteine Depletion", J. Clin. Pharmacol., 2003, pp. 1324-1328, Vol. 43.			
\downarrow	4.	MARE, Suneetha et al., "High performance liquid chromatography analysis of MESNA (2-mercaptoethane sulfonsle) in biological samples using fluorescence detection", Biomedical Chromatography, 2005, pp. 80-86, Vol. 19.			

Signature	/Timothy Thomas/	Considered	5/5/2008	
*EXAMINER: Initi	al if reference considered, whether or not citation		609. Draw line through citation if not in	conformance

Date

5/5/2008

December 1 release considered, whether on thor Quantity and in Continuation where the other while an organization in the analysis and not considered, included copy of this time with next communication to application.

Applicants unique citation designation number (optional). Applicant is to place a check mark here if English Inaquage Translation is attacked.

Applicants unique citation designation number (optional). Applicant is to place a check mark here if English Inaquage Translation is attacked.

The collection of information is required by 37 CFR 16.1 The information is required to obtain or retains a benefit by the public which is to frie (and by the USPTO options) and application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.1 The Collection is estimated to lake 120 minutes of the completed application from to be 1977. Time with vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.